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Purpose: Retinoblastoma is the most common eye tumor in childhood. The best outcome regard-
ing tumor control and visual function can be reached by external beam radiotherapy. The benefits
of the treatment are, however, jeopardized by a high incidence of radiation induced secondary ma-
lignancies and the fact that irradiated bones grow asymmetrically. In order to better exploit the
advantages of external beam radiotherapy it is necessary to improve current techniques by reducing
the irradiated volume and minimizing the dose to the facial bones. The purpose of this work is to
evaluate the adequacy of Monte Carlo simulations and the accuracy of a commercial treatment plan-
ning system by means of experimental measurements. To this end dose measurements in water were
performed using the dedicated collimator employed in the retinoblastoma treatment. Evaluation of
these two calculation methods is necessary to further improve the irradiation technique.
Methods: A Varian Clinac 2100 C/D operating at 6 MV is used. A dedicated collimator for
the retinoblastoma treatment is inserted in the accessory tray holder. This collimator conforms a
‘D’–shaped off-axis field whose irradiated area can be either 5.2 or 3.1 cm2. Depth dose distributions
and lateral profiles were experimentally measured. Experimental results were compared with Monte
Carlo simulations run with the penelope code and with calculations performed with the analytical
anisotropic algorithm implemented in the Eclipse treatment planning system using the gamma test.
Results: penelope simulations agree reasonably well with the experimental data with discrep-
ancies in the dose profiles less than 0.3 cm of distance-to-agreement and 3% of dose. Discrepancies
between the results found with the analytical anisotropic algorithm and the experimental data reach
0.3 cm and 6%. The agreement in the penumbra region between the analytical anisotropic algorithm
and the experiment is noticeably worse than the agreement between the latter and penelope. The
percentage of voxels with a gamma index larger than unity when comparing penelope results with
the experiment is on average 1% assuming a 0.3 cm distance-to-agreement and a discrepancy of 3%
of dose. Under the same conditions the percentage of voxels exceeding a gamma index equal to one
when the analytical anisotropic algorithm is considered is on average 7%.
Conclusions: Although the discrepancies between the results obtained with the analytical
anisotropic algorithm and the experimental data are noticeable, it is possible to consider this al-
gorithm for routine treatment planning of retinoblastoma patients, provided the limitations of the
algorithm are known and taken into account by the medical physicist. Monte Carlo simulation
is essential for knowing these limitations. Monte Carlo simulation is required for optimizing the
treatment technique and the dedicated collimator.
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I. INTRODUCTION
Retinoblastoma is the most common eye tumor in childhood. Multiple, bilateral tumors are caused by a germline
mutation at the RB-1 locus on chromosome 13 and therefore are hereditary [1]. Furthermore, this mutation leads
also to secondary malignancies outside the eye. The best outcome for the primary tumors regarding tumor control
and visual function can be reached by external beam radiotherapy [2]. However, due to the specific genetic situation,
a very high incidence (20% within 30 years) of secondary malignancies after external beam radiotherapy has been
observed [3–6]. Consequently, in the last two decades, major efforts were made to avoid external beam radiotherapy in
these young children using especially systemic [7, 8] and recently even locally applied chemotherapy [9] in combination
with local treatments such as laser- and cryo-coagulation, and brachytherapy [10–12]. These techniques severely
damage the retina, and therefore, have a negative influence on the visual acuity. Moreover, the long-term toxicity of
chemotherapy on other organs cannot be neglected [13] and an increased incidence of leukemia and solid malignancies
after chemotherapy has been reported [14, 15]. It seems therefore justified to reconsider specific external beam
radiotherapy techniques aimed at reducing the irradiated volume which are designed to avoid asymmetric growth of
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2FIG. 1: Photograph of the retinoblastoma collimator, with the optional brass collimator inserted, mounted on a Varian
Clinac 2100 C/D. The gantry and collimator angle of the linac are those used for the irradiation of the patient.
the bones of the face. Schipper made in 1983 a first attempt in this direction by developing a highly precise lens
sparing irradiation technique for retinoblastoma [16, 17]. This technique, with some minor improvements, is still the
state-of-the-art for the irradiation of retinoblastoma in children [18].
In this work an approach based on Monte Carlo (MC) simulation is introduced in order to assess the dose distribution
of the mentioned radiotherapy technique. As a first step, the accuracy of the MC simulation is evaluated by means
of experimental measurements in a water phantom. Secondly, the limitations of using the analytical anisotropic
algorithm (AAA) [19–21] implemented in the Eclipse treatment planning system are evaluated by comparison with
experimental data and MC results. The intention in the near future is to identify a linac-based gentle dose distribution
that results in better functional outcome as compared to current treatments based on chemotherapy but especially in
less radiation-induced secondary tumors by reducing the irradiated volume of healthy tissues.
II. MATERIALS AND METHODS
A. Retinoblastoma collimator
At the University Hospital of Essen a Varian Clinac 2100 C/D operating at 6 MV is used to treat retinoblastoma in
patients. A dedicated collimator, inserted in the accessory tray holder, conforms a ‘D’-shaped off-axis field by means
of a long cerrobend tube whose downstream end is located at 17 cm from the isocenter. An optional brass insert can
be placed in the dedicated collimator to deliver a smaller field size, which is also ‘D’-shaped. Thus, patients can be
treated either using a larger irradiated area of 5.2 cm2 or a smaller one of 3.1 cm2. Figure 1 shows a picture of the
retinoblastoma collimator with the optional brass collimator mounted on a Clinac 2100 C/D. Since the technique is
used with pediatric patients who cannot collaborate during the treatment, they must be anesthetized, immobilized and
their eyes fixed with vacuum lenses designed to position the eye lenses of the patient with respect to the anterior flat
edge of the field. Thus, the collimating device has a fixation system for the eyes and distance scales for determining
the eye position with respect to the isocenter and beam central axis. These fixation and positioning devices are
attached to the collimator and they can also be seen in the photograph.
Figure 2 shows the blueprints of the retinoblastoma collimator with the optional brass collimator inserted. Only
the parts relevant for conforming the field appear while the fixation and positioning devices are not drawn. The z axis
corresponds to the beam central axis with the beam propagating in the direction of increasing z. In these blueprints
the collimator appears in the position used for irradiating a dosimetry water phantom. The coordinate system plotted
in the blueprints is the same used throughout this article. The origin of coordinates is located at the center of the
upstream surface of the bremsstrahlung target of the linac, 100 cm away from the isocenter along the z-axis. Station
B–B in figure 2 corresponds to the aluminum plate that is inserted in the accessory tray holder of the linac.
The movable X-jaws are positioned to define a symmetric field about the y axis of width equal to 5.5 cm (each
X-jaw is displaced 2.75 cm away from the closed position). In contraposition, the field defined by the Y-jaws is not
centered, with the Y-jaws in the negative and positive segments of the y axis displaced 0.7 and 3.5 cm, respectively,
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FIG. 2: Blueprints of the dedicated collimator used for retinoblastoma irradiation. The blueprints show the optional brass
collimator inserted.
4from their closed position. Therefore, a 5.5 × 4.2 cm2 field is defined with its center at x = 0 cm and y = 1.4 cm as
measured at 100 cm from the origin of coordinates. The same field defined by the movable jaws is used independently
of the presence of the optional brass collimator.
B. Experimental measurements
Depth dose distributions and lateral profiles for both field sizes were experimentally measured with an IBA water
phantom RFA Plus. The gantry rotation angle and the collimator angle were set to zero degrees and the source-to-
surface distance equaled 100 cm. With these settings the bar of the positioning and fixation system of the retinoblas-
toma collimator was partially immersed in the water and, therefore, the movement of the scanning support was
restricted on the y direction to avoid collision with the bar. Because neither the reticule center nor the distance indi-
cator are visible while the retinoblastoma collimator is inserted in the Clinac it was necessary to adjust the detector
with its effective measurement point placed at the isocenter before mounting the retinoblastoma collimator. However,
inserting the retinoblastoma collimator in the accessory tray holder of the Clinac requires lowering the water phantom
and rotating the collimator of the linac an angle of 45 degrees. The isocenter level was marked on the water tank
before lowering it. All these technical difficulties reduced the position accuracy of the detector. The final position
uncertainty of the experimental measurements was estimated to be 0.5 mm.
Relative absorbed dose measurements were performed with a diamond detector with a sensitive diameter of about
2 mm (PTW 60003, Freiburg) which provides good agreement with ionization chambers, and a stereotactic diode
with a sensitive diameter of about 0.6 mm (SFD, IBA Dosimetry, Schwarzenbruck) and a better spatial resolution.
Experimental measurements were compared to those obtained from a stereotactic ionization pinpoint chamber (PTW
31016, Freiburg). For absolute dose measurements the pinpoint chamber was used with the effective measurement
point placed in the center of the field at the maximum depth in the water phantom. A cross calibration was done
using reference fields 5 × 5 cm2 and 10 × 10 cm2 without the retinoblastoma collimator. The actual dose of these
fields was determined employing an ionization chamber (PTW M310013, Freiburg).
The diamond detector was preirradiated with at least 5 Gy. All measurements with the retinoblastoma collimator
were done without a reference signal because of the small field. This procedure can be followed because of the high
stability dose rate characteristic of the Varian Clinac 2100 C/D.
C. Monte Carlo simulations
MC simulations were run using the general-purpose MC code system penelope [22–24] for the coupled transport
of electrons, positrons and photons. penelope is a set of FORTRAN subroutines that requires a main steering
program in charge of defining the primary particle source, tallying the required quantities and applying the necessary
variance-reduction techniques; the code penEasy was used for that purpose [25]. For estimating the absorbed dose
in water it is first necessary to simulate the Varian Clinac 2100 C/D. The geometry, material and configuration files
for that linac were automatically generated with the program penEasyLinac [25, 26]. The simulations run with the
codes penelope/penEasy/penEasyLinac have been validated in previous publications, in particular for the case
of the Varian Clinac 2100 C/D operating at 6 MV, which is the nominal energy used in all experiments, simulations
and calculations presented in this article [25–28].
penelope uses a mixed simulation scheme that classifies electron and positron interactions either as hard or soft
events. Hard events, defined as those involving angular deflections or energy losses above certain cutoffs, are simulated
in a detailed manner. All soft interactions between two hard events are grouped together and simulated with a single
artificial event. The cutoffs are determined by five user-defined transport parameters: C1, controls the average angular
deflection between two consecutive hard elastic collisions; C2, is related to the maximum fractional energy loss between
two hard elastic collisions; WCC and WCR are the cutoffs for inelastic and bremsstrahlung interactions, respectively.
Finally, DSMAX is an upper limit for the step length. The user-defined transport parameters were automatically set
by penEasyLinac to C1 = C2 = 0.1, WCC = 100 keV, WCR = 20 keV and the DSMAX value for each constructive
element of the linac equaled 1/10 of its thickness along the beam path. In the simulation all particles are transported
until their kinetic energies fall below certain user-defined absorption energies. These energies were set to 100 keV for
electrons and positrons, and 20 keV for photons.
The MC simulation for estimating the absorbed dose in a water phantom was divided into three subsequent sim-
ulations. First, a simulation was run from the primary electron source downstream to the exit of the gantry, where
a phase-space file was tallied. The primary electron source was modeled as a monoenergetic point-like pencil beam
with zero divergence and initial kinetic energy equal to 6.26 MeV. The movable jaws were positioned according to
the description of the retinoblastoma treatment given in section II A. Secondly, two subsequent simulations used the
5previously tallied phase-space file as a source and particles were transported downstream of the retinoblastoma colli-
mator with and without the additional brass collimator. These simulations produced two phase-space files at 100 cm
from the source, one for the 5.2 cm2 field (without the brass collimator) and another one for the smaller 3.1 cm2 field
(with the brass collimator). The geometry of the retinoblastoma collimator was coded using the constructive quadric
surface package pengeom provided with penelope and strictly following the blueprints given in figure 2. Thirdly, the
phase-space files tallied downstream of both retinoblastoma collimators were transported each into a water phantom
with bin size equal to 0.05× 0.05× 0.1 cm3, and two three-dimensional absorbed dose distributions were tallied, one
for the 5.2 cm2 field and another one for the 3.1 cm2 field.
D. Calculation with the analytical anisotropic algorithm
The AAA [19–21] as implemented in the treatment planning system Eclipse (Varian) was used to calculate the
dose distribution obtained when using the retinoblastoma collimator with its two available field sizes. The versions
of the software used were Eclipse 8.9.09 on ARIA 8 with AAA version 8.9.08. With Eclipse it is not possible to
simulate the detailed structure of the retinoblastoma collimator shown in figure 2 as it was done with penelope.
The retinoblastoma collimator must be approximated to an aperture block of 10 cm of thickness with transmission
of 0.1% placed on a tray with 100% transmission. The aperture is shaped according to the field defined by the
retinoblastoma collimator at 100 cm from the source. Two apertures were modeled, one for each considered field size.
The calculation grid size was chosen to be 0.1 cm whereas the phantom voxel size was 0.086× 0.086× 0.2 cm3. The
two three-dimensional absorbed dose distributions were exported in DICOM format and then converted into ASCII
for comparing with experimental data and MC results.
III. RESULTS
Depth dose distributions and lateral profiles obtained for both field sizes, namely 5.2 and 3.1 cm2, are plotted in
figures 3, 4 and 5. In all plots symbols were used for experimental data, histograms for MC results and lines for the
AAA calculations. Doses per primary particle are expressed in Gy/(mA s) as computed from penelope, whence the
dose in Gy can be calculated knowing the current intensity at the target in mA and the irradiation time in s. The
experimental relative dose profiles were scaled to match the maximum absorbed dose obtained with penelope using
the same scaling factor for all curves for a given field size. The same procedure was applied to scale the data obtained
with the AAA.
The gamma test [29] was used for a quantitative comparison of the plotted dose profiles. Table I shows the
comparison of the results obtained with penelope and the AAA against the experimental data used as reference
data set. All absorbed dose profiles were compared using the following three criteria: distance-to-agreement (DTA)
of 0.1 cm and a discrepancy of 1% of the dose, 0.2 cm and 2%, and 0.3 cm and 3%. Additionally, for the comparison
of AAA results with respect to the experimental data the criteria 0.3 cm and 6% was also used. The values reported
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FIG. 3: Depth dose distributions at x = 0 cm and y = 1.3 cm. Symbols represent experimental data measured with diamond
detector, histograms correspond to MC simulations, lines plot AAA results. Results for the 5.2 cm2 (a) and the 3.1 cm2 (b)
field sizes. MC statistical uncertainty bars (1σ) are smaller than symbol size. Experimental data were scaled as explained in
the text. For clarity reasons only some experimental points are plotted.
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FIG. 4: Lateral profiles along the x axis for y = 1.3 cm plotted at depths z = 1.5 (red circles), 3.0 (blue diamonds) and 5.0 cm
(green squares). Symbols represent experimental data measured with SFD diode, histograms correspond to MC simulations,
lines plot AAA results. Results for the 5.2 cm2 (a) and the 3.1 cm2 (b) field sizes. Other details are the same as in figure 3.
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FIG. 5: Lateral profiles along the y axis for x = 0 cm plotted at depths z = 1.5 (red circles), 3.0 (blue diamonds) and 5.0 cm
(green squares). Symbols represent experimental data measured with SFD diode, histograms correspond to MC simulations,
lines plot AAA results. Results for the 5.2 cm2 (a) and the 3.1 cm2 (b) field sizes. Other details are the same as in figure 3.
on table I are the percentage of voxels that exceed a gamma index equal to 1, that is, the percentage of voxels that
fail the test, for each dose profile, criteria and computing algorithm.
IV. DISCUSSION AND CONCLUSIONS
For both fields there is an excellent agreement between the depth dose distributions obtained with MC simulations
and the experimental data. Regarding the AAA results on depth dose distributions, the agreement with the experi-
mental data is nearly as good as that obtained with MC simulations. However, a close inspection of the depth dose
curves obtained with the AAA reveals a sinusoidal pattern on the curve for depths greater than 10 cm. This artifact
already appears when the kernel beamlets of the AAA are generated and it is observed in depth dose calculations of
reference fields smaller than 3× 3 cm2 in the beam configuration.
The agreement between simulated results and experimental data in relation to lateral profiles is substantially worse
with respect to the degree of agreement observed for the depth dose distributions (table I). penelope simulations
agree reasonably well with the experimental data with a DTA less than 0.3 cm and a dose difference below 3%. The
largest differences between these two data sets can be ascribed on the shoulder region of the lateral profiles. When
comparing results from the AAA with experimental data a zero percent of voxels exceeding gamma index equal to
one is reached with the criteria 0.3 cm and 6%. In the case of the AAA differences appear not only on the shoulders
but also on the penumbra tails.
Due to the off-axis character of the irradiated fields, the penumbra tails calculated with the AAA along the y axis
show marked discrepancies with respect to the experimental data, while similar discrepancies do not appear in the
profiles computed along the x axis (figures 4, 5 and table I). Additionally, for both considered fields an artifact, a
7TABLE I: Gamma test for comparing penelope results against the experimental data and AAA results against the experimental
data. See text for details.
field profile penelope AAA
0.1 cm, 1% 0.2 cm, 2% 0.3 cm, 3% 0.1 cm, 1% 0.2 cm, 2% 0.3 cm, 3% 0.3 cm, 6%
5.2 cm2
depth dose 3 2 0 7 2 0 0
x at z = 1.5 cm 7 6 2 34 16 10 0
y at z = 1.5 cm 30 11 3 39 22 6 3
x at z = 3.0 cm 11 4 0 27 13 5 2
y at z = 3.0 cm 21 5 2 35 19 8 3
x at z = 5.0 cm 12 6 0 15 8 6 0
y at z = 5.0 cm 21 5 0 35 19 7 2
3.1 cm2
depth dose 2 1 0 5 2 0 0
x at z = 1.5 cm 22 8 3 33 11 3 0
y at z = 1.5 cm 25 9 3 53 34 18 3
x at z = 3.0 cm 29 5 0 40 19 9 2
y at z = 3.0 cm 31 12 3 43 25 10 0
x at z = 5.0 cm 23 5 0 46 18 7 0
y at z = 5.0 cm 31 8 0 45 20 12 0
‘kink’ in the lateral profile, appears on the AAA data at y = 0 cm (figure 5). The reason for this kink seems to be
the following: the evaluated version of AAA uses for its calculations an input fluence map whose pixel size is fixed to
2.5 mm2 with a gridding in which the point x = y = 0 coincides with the interface among four pixels. As it can be
seen from the blueprints, the irradiated field is 1 mm away from the central beam axis, in other words, the central
beam axis is obscured by a cerrobend block. Therefore, the fluence pixel from y = 0 to y = 2.5 mm corresponds to a
region with transmission coefficient of 0.1% along its first millimeter and a transmission coefficient of 100% along the
last 1.5 mm. A test calculation was performed in which the flat side of the ‘D’–shaped field was positioned on the
central beam axis and the kink angle was much reduced and displaced to a higher dose region of the profile, almost
disappearing.
The kink in the lateral profiles computed with the AAA appears in a delicate position from the therapeutical point
of view. The fixation system of the retinoblastoma collimator aligns the main symmetry axis of the eye lens with the
y axis. The eye lens is positioned such that its posterior pole coincides with x = y = 0 cm. Therefore, the whole
eye lens is located at y < 0 cm, that is, protected by the cerrobend. Owing to the kink the width of the penumbra
tail of the AAA results is overestimated by nearly 2 mm, more than half of the thickness of the eye lens, therefore
overestimating the actual dose delivered to it.
Previous studies on 6 MV beams have shown that the discrepancy of the doses obtained in water using the AAA
and experimental data is less than 2% of the maximum absorbed dose [27, 30–32]. However, in these studies the
smallest considered field is 3× 3 cm2 centered. In contradistinction, the smallest field considered in the present study
is 3.1 cm2, highly conformed and off-axis. Under these more difficult conditions the discrepancy between the AAA
and the experiment reaches 0.3 cm and 6%. Although these discrepancies are relevant from the therapeutical point of
view, it is still possible to consider the AAA for routine treatment planning of retinoblastoma patients, provided the
limitations of the algorithm are known and taken into account by the medical physicist. Knowledge on the limitations
of the algorithm can be achieved by a combination of experiments and MC simulations. Future research will be
aimed at improving the design of the retinoblastoma collimator and the irradiation technique. For this purpose MC
simulations are indispensable.
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